PHAT:NASDAQ, Phathom Pharmaceuticals, Inc.
PHAT stock overview
Phathom Pharmaceuticals, Inc. (PHAT:NASDAQ) closed at $5.74 on October 23, 2026,
down 18.12% on the day.
The stock trades 68.7% below its 52-week high of $18.31
and 14.3% above its 52-week low of $5.02.
Over the past year, it lost 57.6%.
Phathom Pharmaceuticals, Inc. is part of the Health Care sector.
Key figures
- Price
- $5.74
- Day change
- -18.12%
- Volume
- 4,861,997
- Average volume
- 1,393,164
- Market cap
- 464M+
- 52-week range
- $5.02 – $18.31
- 50-day average
- $8.03
- 200-day average
- $10.73
Price action over the past year
In 252 trading sessions since October 23, 2025, PHAT closed higher on 125 days (50%).
Its best day was January 7, 2026 (+10.45%) and its worst was July 30, 2026 (-22.42%).
The stock moved 10% or more in a single session 6 times.
Recent signals
PHAT news
-
Oct 23, 2026:
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug's Exclusivity
-
Oct 23, 2026:
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drugs Exclusivity
-
Oct 23, 2026:
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
-
Oct 21, 2026:
Phathom's Prescribing Friction Faces Its First Test After Guidance Cut Rattled Investors
-
Oct 19, 2026:
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
-
Oct 12, 2026:
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA (vonoprazan) at ACG 2026
-
Oct 12, 2026:
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
-
Oct 8, 2026:
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprise of vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Similar stocks
Find more stocks like PHAT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.